• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The histopathologist is essential in molecular pathology quality assurance for solid tumours.

作者信息

Ooft Marc Lucas, Boissiere Jeanne, Sioletic Stefano

机构信息

Department of Histopathology, King's College Hospital, King's College, London, UK.

Pathology-DNA, Rijnstate Hospital, 6815AD, Arnhem, The Netherlands.

出版信息

Virchows Arch. 2021 Dec;479(6):1263-1265. doi: 10.1007/s00428-021-03226-y. Epub 2021 Nov 4.

DOI:10.1007/s00428-021-03226-y
PMID:34735627
Abstract
摘要

相似文献

1
The histopathologist is essential in molecular pathology quality assurance for solid tumours.组织病理学家在实体肿瘤的分子病理学质量保证中至关重要。
Virchows Arch. 2021 Dec;479(6):1263-1265. doi: 10.1007/s00428-021-03226-y. Epub 2021 Nov 4.
2
Morphological control for molecular testing: a practical approach.形态学控制在分子检测中的应用：一种实用方法。
J Clin Pathol. 2021 May;74(5):331-333. doi: 10.1136/jclinpath-2020-206890. Epub 2020 Aug 6.
3
HER2 testing of gastro-oesophageal adenocarcinoma: a commentary and guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Committee.胃食管腺癌的HER2检测：临床病理学家协会分子病理学与诊断委员会的评论与指导文件
J Clin Pathol. 2018 May;71(5):388-394. doi: 10.1136/jclinpath-2017-204943. Epub 2018 Feb 8.
4
Next generation diagnostic molecular pathology: critical appraisal of quality assurance in Europe.下一代诊断分子病理学：欧洲质量保证的批判性评估
Mol Oncol. 2014 Jun;8(4):830-9. doi: 10.1016/j.molonc.2014.03.004. Epub 2014 Mar 18.
5
Predictive pathology in routine diagnostics of solid tumors.实体瘤常规诊断中的预测病理学。
Histol Histopathol. 2012 Mar;27(3):289-96. doi: 10.14670/HH-27.289.
6
European consensus conference for external quality assessment in molecular pathology.欧洲分子病理学外部质量评估共识会议。
Ann Oncol. 2013 Aug;24(8):1958-63. doi: 10.1093/annonc/mdt153. Epub 2013 Apr 23.
7
[Current challenges in pathology - practical solutions for commonly occurring problems: Introduction to the 49th symposium of the German division of the International Academy of Pathology, 22-24 February 2013, in Bonn].[病理学当前面临的挑战——常见问题的实用解决方案：2013年2月22日至24日于波恩举行的国际病理学会德国分会第49届研讨会介绍]
Pathologe. 2013 Feb;34(1):8. doi: 10.1007/s00292-012-1701-x.
8
Diagnostic concordance of reporting lymphovascular invasion in breast cancer.乳腺癌中报告淋巴管血管侵犯的诊断一致性。
J Clin Pathol. 2018 Sep;71(9):802-805. doi: 10.1136/jclinpath-2017-204981. Epub 2018 Mar 29.
9
[The pathologist's place in the neoadjuvant management of cancer: a special issue].[病理学家在癌症新辅助治疗管理中的作用：特刊]
Ann Pathol. 2011 Dec;31(6):417-8. doi: 10.1016/j.annpat.2011.10.002. Epub 2011 Nov 29.
10
Ethical considerations for modern molecular pathology.现代分子病理学的伦理考量。
J Pathol. 2018 Dec;246(4):405-414. doi: 10.1002/path.5157.

引用本文的文献

1
Tissue management in precision medicine: What the pathologist needs to know in the molecular era.精准医学中的组织管理：分子时代病理学家需要了解的内容。
Front Mol Biosci. 2022 Oct 26;9:983102. doi: 10.3389/fmolb.2022.983102. eCollection 2022.
2
Daily Practice Assessment of Status in NSCLC Patients: A New Challenge for the Thoracic Pathologist Is Right around the Corner.非小细胞肺癌患者病情的日常实践评估：胸科病理学家面临的一项新挑战即将来临。
Cancers (Basel). 2022 Mar 23;14(7):1628. doi: 10.3390/cancers14071628.

本文引用的文献

1
Validity of whole genomes sequencing results in neoplasms in precision medicine.精准医学中肿瘤全基因组测序结果的有效性。
J Clin Pathol. 2021 Nov;74(11):718-723. doi: 10.1136/jclinpath-2020-206998. Epub 2020 Oct 29.
2
Neoplastic cell percentage estimation in tissue samples for molecular oncology: recommendations from a modified Delphi study.用于分子肿瘤学的组织样本中肿瘤细胞百分比估计：改良 Delphi 研究的建议。
Histopathology. 2019 Sep;75(3):312-319. doi: 10.1111/his.13891. Epub 2019 Jul 18.
3
Tumor Heterogeneity in Breast Cancer.
乳腺癌中的肿瘤异质性
Front Med (Lausanne). 2017 Dec 8;4:227. doi: 10.3389/fmed.2017.00227. eCollection 2017.
4
Lung Cancer: Understanding Its Molecular Pathology and the 2015 WHO Classification.肺癌：了解其分子病理学及2015年世界卫生组织分类
Front Oncol. 2017 Aug 28;7:193. doi: 10.3389/fonc.2017.00193. eCollection 2017.
5
Guidelines for Validation of Next-Generation Sequencing-Based Oncology Panels: A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists.基于新一代测序的肿瘤学检测板验证指南：分子病理学协会和美国病理学家学会联合共识推荐
J Mol Diagn. 2017 May;19(3):341-365. doi: 10.1016/j.jmoldx.2017.01.011. Epub 2017 Mar 21.
6
Adequately defining tumor cell proportion in tissue samples for molecular testing improves interobserver reproducibility of its assessment.在组织样本中充分定义用于分子检测的肿瘤细胞比例，可提高其评估的观察者间再现性。
Virchows Arch. 2017 Jan;470(1):21-27. doi: 10.1007/s00428-016-2042-6. Epub 2016 Nov 16.
7
Integration of next-generation sequencing in clinical diagnostic molecular pathology laboratories for analysis of solid tumours; an expert opinion on behalf of IQN Path ASBL.下一代测序技术在临床诊断分子病理学实验室中用于实体瘤分析的整合；代表IQN Path ASBL的专家意见。
Virchows Arch. 2017 Jan;470(1):5-20. doi: 10.1007/s00428-016-2025-7. Epub 2016 Sep 27.
8
Guidance for laboratories performing molecular pathology for cancer patients.针对为癌症患者开展分子病理学检测的实验室的指南。
J Clin Pathol. 2014 Nov;67(11):923-31. doi: 10.1136/jclinpath-2014-202404. Epub 2014 Jul 10.
9
The estimation of tumor cell percentage for molecular testing by pathologists is not accurate.病理学家对分子检测进行肿瘤细胞百分比估计并不准确。
Mod Pathol. 2014 Feb;27(2):168-74. doi: 10.1038/modpathol.2013.134. Epub 2013 Jul 26.
10
EGFR and KRAS quality assurance schemes in pathology: generating normative data for molecular predictive marker analysis in targeted therapy.EGFR 和 KRAS 质量保证计划在病理学中的应用：为靶向治疗中分子预测标志物分析生成规范数据。
J Clin Pathol. 2011 Oct;64(10):884-92. doi: 10.1136/jclinpath-2011-200163.